Akut miyokard enfarktüsü şüphesi olan hastalarda kardiyak biyobelirteç ölçümünde kullanılan hasta başı test cihazlarının değerlendirilmesi

Amaç:Hastaneler ve poliklinikler artık hasta bakımı sunumunda tanısal analizlerin kullanılmasına izin veren hasta başı test  (POCT) cihazları kullanmaktadırlar.Çalışmamızda kantitatif Nano-Ditech (Cranbury, NJ, USA)  CK-MB, cTnI ve miyoglobin POC testlerinin değerlendirilmesi ve Getein 1100 (Nanjing, Çin) CK-MB, cTnI ve miyoglobin POC testlerinin analitik performans karşılaştırılması amaçlanmıştır.Gereç ve Yöntem:Bilecik Gölpazarı İlçe Devlet Hastanesi'ne göğüs ağrısı şikayeti ile Ağustos-Eylül 2017 tarihleri ​​arasında başvuran 100 hastadan (53 erkek ve 47 kadın), Getein 1100 ve Nano-Ditech kardiyak cihazları için lityum heparinli plazma örnekleri(Terumo Europe NV Leuven, Belçika) rastgele olarak alındı. Bulgular:Bizim çalışmamızda, iki cihaz arasındaki korelasyon, troponin için r = 0.023 ve p = 0.017, CK-MB için r = 0.130 ve p = 0.001 olarak bulunmuştur ve miyoglobin için iki cihaz arasında herhangi bir korelasyon bulunmamıştırSonuç:İki cihazın analitik performansı değerlendirildiğinde, Akut Miyokard Enfarktüsü’nün teşhisi, tanı ve dışlanması için önemli olan troponin, CK-MB ve miyoglobinin mutlak değerlerinin karşılaştırılmasının Klinik ve Laboratuvar Standartları Enstitüsü (CLSI)'nin önerdiği yöntem karşılaştırma protokolü ile uyumsuz olduğunu bulduk (EP-9).

Assessment of a point-of-care assay for cardiac biomarkers for patients suspected of acute myocardial infarction

Purpose:Hospitals and outpatient clinics are now relating point-of-care testing (POCT) devices that contract for the use of diagnostic analyses at the site of patient care delivery, so, facilitating earlier decision-making besides fast treatment. In our study, the aim was to assess the quantitative Nano-Ditech (Cranbury, NJ, USA), CK-MB, cTnI and myoglobin POC assays and to compare them with the Getein 1100 (Nanjing, China) CK-MB, cTnI and myoglobin POC assaysMaterials and Methods:Lithium heparin plasma samples (Terumo Europe N.V. Leuven, Belgium,) for Getein 1100 and Nano-Ditech cardiac marker determinations were randomly collected from among routine samples from 100 patients (53 male and 47 female) with chest pain complaint who admitted to Bilecik Golpazarı Government Hospital between August-September 2017 and all analyses were performed using the Nano-Ditech analyzer and comparative analyses were performed by the Getein 1100) assays.Results:In our study, the correlation between the two devices was found to be r = 0.023 and p=0.017 for troponin, r = 0.130 and p=<0.001 for CK-MB and there is no correlation for myoglobin.Conclusion: According to evaluation of both devices’ analytical performances, it was found that the comparison of the all values ​​of troponin, CK-MB and myoglobin, which are important for the diagnosis and exclusion of acute myocardial infarction(AMI), is discordant with the method comparison protocol proposed by the Clinical and Laboratory Standards Institute (CLSI) (EP-9).

___

  • 1. Wu AHB, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes J R. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for use of cardiacmarkers in coronary artery diseases. ClinChem 1999;45:1104-21.
  • 2. Fesmire FM, Decker WW, Howell JM, Kline JA. Clinical policy: critical issues in the evaluation and management of adult patients presenting with suspected acute myocardial infarction or unstable angina. Ann Emerg Med. 2000;35:521-44.
  • 3. Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined—a consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000;21:1502- 13.
  • 4. Epstein AE, Di Marco JP, Ellen bogen KA, Mark Esteset N.A, Roger A, Freedman al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for devicebased therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology Foundation/American Heart Association Task Forceon Practice Guidelines and the Heart Rhythm Society. Circulation. 2013;127:e283–e352
  • 5. European Heart Rhythm A, European Society of C, Heart Rhythm S, et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: Implant and follow-up recommendations and management. Heart Rhythm. 2012;9:1524-76.
  • 6. Lefebvre CW, Hoekstra J. Approach to non-STsegment elevation acute coronary syndrome in the emergency department: Risk stratification and treatment strategies. Hosp Pract. 2010;38:40-9.
  • 7. Tiwari RP, Jain A, Khan Z, Kohli V, Bharmal R.N, Kartikeyan S et al. Cardiac troponins I and T: Molecular markers for early diagnosis, prognosis, and accurate triaging of patients with acute myocardial infarction. Mol Diagn Ther 2012;16:371-81.
  • 8. Friess U, StarkM. Cardiac markers: A clear cause for point-of-care testing. Anal Bioanal Chem. 2009;393:1453–62.
  • 9. de Winter RJ, Koster RW, Sturk A, Sanders GT. Value of myoglobin, troponin T, and CK-MBmass in ruling out an acute myocardial infarction in the emergency room. Circulation. 1995;92:3401-07.
  • 10. Gruberg L, Sudarsky D, Kerner A, Hammerman H, KapeliovichM, Beyar R. Troponin-positive, CK-MBnegative acute myocardia linfarction: Clinical, electrocardiographic and angiographic characteristics. J Invasive Cardiol. 2008;20:125–8.
  • 11. Yang Z, Yamazaki M, Shen QW, Swartz DR. Differences between cardiac and skeletal troponin interaction with the thin filament probed by troponin exchange in skeletal myofibrils. Biophys J. 2009;97:183–194.
  • 12. Eggers KM, Venge P, Lindahl B, Lind L. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J Am Col Cardiol. 2013;61:1906–13.
  • 13. Diercks DB, Peacock WF 4th, Hollander JE, Singer Adam J, Birkhahn R, Shapiro N et al. Diagnostic accuracy of a point-of-care troponin I assay for acute myocardial infarction within 3 hours after presentation in early presenters to theemergency department with chestpain. AmHeart J. 2012;163:74– 80.
  • 14. Chan D, Ng LL. Biomarkers in acute myocardial infarction. BMC Med. 2010;8:34. 15. Lackner KJ. Laboratory diagnostics of myocardial infarction-Troponins and beyond. Clin Chem. Lab Med. 2013;51:83–9.
  • 16. Apple FS, Christenson RH, ValdesJr. R, Andriak AJ, Berg A, Duh SH et al. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin by the Triage Cardiac Panel for detection of myocardial infarction. ClinChem. 1999;45:199–205.
  • 17. Apple FS, Anderson FP, Collinson P, Jesse RL, Kontos MC, Levitt MA et al. Clinicalevaluation of the First Medical whole blood point-of-caretesting device for detection of myocardial infarction. ClinChem. 2000;46:1604–9.
  • 18. Hamm C, Goldmann B, Heeshen C, Kreymann G,Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I.N Engl J Med. 1997;337:1648–53.
  • 19. Bingisser R, Cairns C, Christ M, Hausfater P, Lindahl B, Mair J et al. Cardiac troponin: A critical review of the case for point-of-care testing in the ED. Am J Emerg Med. 2012;30:1639–49.
  • 20. Hedberg P1, Valkama J, Puukka M. Analytical performance of time-resolvedfluorometry-based InnotracAio! cardiac marker immunoassays. Scand J Clin Lab Invest. 2003;63:55-64.
  • 21. Panteghini M, Apple F, Christenson R, Dati F, Mair J, Wu A. Use of biochemical markers in acute coronary syndromes: IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage. ClinChem Lab Med. 1999;37:687–93.
  • 22. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline. 2nd ed. Vol. 22 No. 19 CLSI document EP9-A2. Wayne, PA: Clinical and Laboratory Standards Institute. 2002.
  • 23. Ellidağ H, Eren E, Aydın Ö, Arslan İnce F, Gök İ,Yılmaz N. Talasemi taramasında Agilent 1100 (Chromsystems) ve Tosoh HLC-723 G8 HPLC sistemlerinin karşılaşılaştırılması.Türk Biyokimya Dergisi. 2014;39:544-8.
  • 24. Fleiss JL. The design and analysis of clinical experiments. New York, John Wiley and Sons. 1986.
  • 25. Lawrence I, Lin K. A concordance correlation coefficient to evaluate reproducibility. Biometrics.1989;45:255-68.
  • 26. Katrukha A, Bereznikova A, Filatov V, EsakovaT, Kolosova O, Pettersson K et al. Degradation of cardiac troponin I: implication for reliable immunodetection. Clin Chem. 1998;44:2433–40.
  • 27. Hedberg P, Melkko T, Valkama J, Puukka M. Higher CK-MB mass value in heparin plasmathan in serum measured with the Abbott AxSYM system. Clin Chem Lab Med. 2001;39:872-4.
  • 28. Wu AH, Smith A, Christenson RH, Murakami MM, Apple FS. Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction. Clin Chim Acta. 2004;346:211- 9.
  • 29. Wu A, Apple F, Gibler W, Jesse R, Warshaw M, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for use of cardiac markers in coronary artery diseases. ClinChem. 1999;45:1104 -21.
  • 30. Dasgupta A, Banerjee SK, Datta P. False hyphen positive troponin. I in the MEIA due to the presence of rheumatoid factors in serum. Elimination of this interference by using a polyclonal antisera against rheumatoid factors. Am J Clin Pathol. 1999;112:753– 6.
Cukurova Medical Journal-Cover
  • ISSN: 2602-3032
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1976
  • Yayıncı: Çukurova Üniversitesi Tıp Fakültesi
Sayıdaki Diğer Makaleler

Fetus kadavralarında parotid bez içerisindeki fasiyal sinirin terminal dallarının morfolojik değerlendirilmesi

Canan ERTEMOĞLU ÖKSÜZ, Ahmet KALAYCIOĞLU, Özlem UZUN, Şahi Nur KALKIŞIM

Eklem dışı distal tibia kırıklarının (AO-43A) tedavisinde intramedüller çivi ve minimal invaziv perkütan plak osteosentez uygulamalarının karşılaştırılması

Mustafa ÖZER, Kayhan KESİK, Veysel BAŞBUĞ, Faik TÜRKMEN, Burkay Kutluhan KAÇIRA, İsmail Hakkı KORUCU, Tahsin Sami ÇOLAK, Recep MEMİK

Çocuklarda psödotümör serebri: etyoloji, klinik bulgular, prognoz

Gülen GÜL MERT, Neslihan ÖZCAN, Şeyda BEŞEN, Kemal YAR, Özlem HERGÜNER, Faruk İNCECİK, Şakir ALTUNBAŞAK

Akut miyokard enfarktüsü şüphesi olan hastalarda kardiyak biyobelirteç ölçümünde kullanılan hasta başı test cihazlarının değerlendirilmesi

Saadet ÇELİK

Huntington hastalığı tanısı almış hastalarda ve ailelerinde CAG trinükleotid tekrar sayılarının fragman analizi ile tespiti

Davut ALPTEKİN, Perçin PAZARCI, Mehmet Ali BEREKETOĞLU, Mehmet Ali ERKOÇ, Nermin Seda ILGAZ, Ümit LÜLEYAP

Cilt kanserlerinde lenfosintigrafi ve cerrahi gama prob ile sentinel lenf nodu biyopsisinin minimal invaziv cerrahi yaklaşımındaki rolü

İsa Burak GÜNEY, Kadir Alper KÜÇÜKER

Acil serviste amilaz testlerinin kullanılması

Halit KARAKISA, Müge GÜLEN, Akkan AVCI, Salim SATAR, Banu KARA

Üniversite öğrencilerinde uykusuzluk, yorgunluk ve ağrıda kullanılan tamamlayıcı ve alternatif yöntemler

Kevser Sevgi ÜNAL, Ebru GÖZÜYEŞİL, Edanur TAR

Akut alevlenme ile yatırılan kronik obstrüktif akciğer hastalığı olan hastalarda hasta-hekim iletişimi

Hülya BULUT, Erol OZAN, Erol ÖZMEN, Pınar ÇİMEN

Tip 2 diyabet hastalarında anksiyete ve depresyon riski ve ilişkili faktörler

Seher SAYIN, Serhat SAYIN, Burak BURSALI, Hatice BİLEN İPEK